Interestingly, this pathway could be preferential for the triple negative subtype since UNC1999 treatment does not appear to affect tumorsphere formation in ER+ breast cancer cell lines possibly identifying a pathway specific to the aggressive TNBC subtype which could be therapeutically targeted through inhibition of EZH2 activity. The gene discussed is EZH2; the disease is breast cancer.